Bupropion HCL ER
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- SPE2D2-21-R-0105
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
-
- Kyle Lewicki kyle.lewicki@dla.mil (445) 737-0977
- Jason Wray jason.wray@dla.mil (445) 737-6304
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical is procuring Bupropion HCL ER (Bupropion Hydrochloride Extended Release) tablets through a national contracts solicitation under SPE2D2-21-R-0105. This pharmaceutical procurement seeks to establish contracts for the manufacture and supply of Bupropion HCL ER tablets in multiple package sizes and strengths to meet the medical supply needs of the Department of Defense. The solicitation was originally posted on January 11, 2022, with proposals due by February 15, 2022, though the contract has undergone multiple modifications since award. The procurement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and PSC code 6505 (Drugs and Biologicals). The contract structure includes a base year with four option years, providing flexibility for extended pharmaceutical supply requirements.
This opportunity utilized full and open competition with no set-aside designations, making it available to all qualified pharmaceutical manufacturers. Radha Pharmaceuticals Inc. was awarded the contract (SPE2D2-23-D-0002) with an estimated total value of $23,278,523.95 over the five-year period, with tablets manufactured by ScieGen Pharmaceuticals at their Hauppauge, NY facility. The contract covers estimated annual quantities ranging from 35,538 to 198,391 units depending on package size, with unit pricing between $1.60 and $28.00 per unit based on package configuration and contract year. Multiple contract modifications have been executed, including the exercise of option years 1, 2, and 3, extending performance through October 5, 2026, and the incorporation of Federal Acquisition Supply Chain Security Act requirements. The most recent modifications also implemented DoD Class Deviations related to merit-based contracting and sustainability requirements.
Notice text
3 versions
Update #3 · Latest ·
Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract.
Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation.
Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract.
Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation.
BUPROPION HCL ER NATIONAL CONTRACTS SOLICITATION
Update #2 ·
Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract.
Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation.
BUPROPION HCL ER NATIONAL CONTRACTS SOLICITATION
Update #1 ·
BUPROPION HCL ER NATIONAL CONTRACTS SOLICITATION
Attachments
Show all 15
Notice history
| Notice | Type | Posted |
|---|---|---|
| Bupropion HCL ER | Award Notice | |
| Bupropion HCL ER | Solicitation | |
| Bupropion HCL ER | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity